# Akso Health Group: Form 20-F for the period ended Mar 31, 2022

- Company: [Akso Health Group](/companies/ahg.md) (CIK 1702318)
- Form: 20-F
- Filed: 2022-12-29
- Accepted by EDGAR: Dec 29, 2022, 16:06 ET
- Period: 2022-03-31
- Accession: 0001104659-22-130935
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1702318/000110465922130935/ahg-20220331x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1702318/000110465922130935/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-04-01 to 2022-03-31 | $6.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months, 2021-04-01 to 2022-03-31 | $5.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months, 2021-04-01 to 2022-03-31 | $916.2k | us-gaap:GrossProfit |
| Research and development | 12 months, 2021-04-01 to 2022-03-31 | $421.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2021-04-01 to 2022-03-31 | −$15.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months, 2021-04-01 to 2022-03-31 | $131.4k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2021-04-01 to 2022-03-31 | −$16.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2021-04-01 to 2022-03-31 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2021-04-01 to 2022-03-31 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2021-04-01 to 2022-03-31 | 59,612,152 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2021-04-01 to 2022-03-31 | −$8.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-04-01 to 2022-03-31 | $4.9k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2022-03-31 | $21.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-03-31 | $50.6m | us-gaap:AssetsCurrent |
| Total assets | at 2022-03-31 | $50.7m | us-gaap:Assets |
| Current liabilities | at 2022-03-31 | $38.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-03-31 | $38.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-03-31 | $12.3m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2022-03-31 | 68,598,050 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1702318/000110465922130935/ahg-20220331x20f.htm

Filed Dec 29, 2022.
Source: SEC EDGAR, the filing index for accession 0001104659-22-130935. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.